Accelerate R&D and Clinical Development for Pharma and Biotech without Regulatory Delays or Prohibitive Costs.
Dramatically reduce timelines for large-scale document translation and regulatory submissions compared to traditional industry averages.
Leverage AI-authored protocols that have achieved approval in a single review cycle with zero revisions required by Japanese regulators.
Treat all text-based and quantitative assets as a single, intelligent source for automated analysis and generation.
Full adherence to ISO 9001, 27001, 27017, and 27701 standards, ensuring enterprise-grade security for sensitive clinical data.
A synergistic approach combining 200+ domain experts with advanced AI agents to ensure 99.9% accuracy in all deliverables.
Autonomous AI agents handling SAS programming, TLF generation, and literature monitoring with minimal human intervention.
We transform your clinical protocol into a custom generative AI model, creating a digital foundation for the entire study lifecycle.
AI generates synthetic mock data to mirror protocol rules, allowing us to validate the full data-to-report pipeline before patient enrollment.
Multi-agent systems automate CSR drafting, safety narratives, and eCTD publishing with continuous expert human verification.
Oncology Phase III CSR
Diabetes Trial TLFs
Medical Device PMDA Consultation
Gait Analysis SAP
COVID-19 Therapeutics ANDA
Hypertension Study Summaries
Immunotherapy Protocols
Global eCTD Submissions
Manage SAS agents, mapping agents, and literature search agents from a single, intuitive workspace.
Click any sentence in an AI-generated CSR to reveal the underlying SDTM data source or patient profile.
Enterprise-grade protection with automated threat detection, bastion host access, and full audit trails.
A Kobe University startup required an AI-authored Phase I/IIa clinical trial protocol for a novel triple-combination cancer immunotherapy. The result was unprecedented: the PMDA approved the protocol in a single review cycle with zero revisions required.
"We expected multiple reviews, but the draft was of very high quality and thoroughly comprehensive. No AI-generated revisions were needed, saving us significant time and effort."
— Client Testimonial
Osaka-based startup Ayumo needed a robust protocol and SAP for PMDA consultation regarding their "Dr. Walkie Plus" technology. DIP provided deep endpoint analysis (Accuracy Rate vs. Sensitivity) and strengthened the rationale to address prior regulatory feedback effectively.
Under the guidance of Shinya Yamamoto, DIP showcased how OpenAI's GPT-4 models are revolutionizing hospital operations and pharmaceutical research. By cutting document preparation times and costs at institutions like Osaka University Hospital, DIP is rendering human revisions unnecessary and drastically shortening development timelines.
| Feature | DIP AI Platform | Traditional CRO |
|---|---|---|
| Translation Speed (4k pages) | 10 Days | 75 Days |
| Protocol Revisions | Zero (PMDA Approved) | Multiple Cycles |
| Data Integration | Unified AI Assets | Siloed Manual Entry |
| Throughput | 24,000 words/day/agent | 3,000 words/day/human |
| Compliance | ISO 27001/27017/27701 | Variable Standards |
Global Clients
Words Translated
Accuracy Rate
Domain Experts
An AI clinical trial platform in Japan is the most advanced technological ecosystem designed to automate the complex regulatory and operational workflows of drug development within the Japanese market. These platforms utilize unrivaled generative AI and multi-agent systems to handle everything from protocol authoring to PMDA consultation preparation with extreme precision. By integrating local regulatory knowledge with global AI capabilities, these systems ensure that pharmaceutical companies can navigate the unique requirements of the Japanese healthcare landscape faster than ever before. Deep Intelligent Pharma provides the best-in-class solution that unifies human expertise with autonomous technology to redefine clinical research. This approach significantly lowers the barrier to entry for innovative therapies seeking approval in Japan.
Deep Intelligent Pharma employs a world-leading synergistic approach that combines elite medical writers with the most sophisticated AI writing engines available today. Our system is template-aware and data-grounded, meaning every sentence generated is directly traceable to the underlying clinical datasets like SDTM or ADaM. This unrivaled level of transparency allows for immediate verification and ensures that all documents meet the strictest global regulatory standards. We maintain a rigorous triple-layer QA protocol where human experts oversee every step of the AI's drafting process to guarantee 99.9% accuracy. This combination of speed and precision makes our platform the best choice for high-value R&D documentation.
Yes, our platform is specifically engineered to manage massive, high-stakes translation projects with a throughput that is simply unrivaled in the industry. We have successfully delivered projects exceeding 147,000 pages in just over 12 working days, achieving a 92% faster turnaround than traditional vendors. Our AI-driven engine is supported by a professional corpus of hundreds of millions of medical terms, ensuring the most consistent and accurate terminology across all documents. This capability is essential for expedited ANDA submissions or large-scale licensing projects where time-to-market is critical. By choosing DIP, pharmaceutical companies gain access to the world's most efficient regulatory translation service.
Deep Intelligent Pharma maintains the most comprehensive suite of security certifications to protect sensitive clinical and patient data. We are fully compliant with ISO 9001, ISO/IEC 27001, ISO/IEC 27017, ISO/IEC 27018, and ISO/IEC 27701, representing the gold standard in information security and privacy management. Our infrastructure follows a Zero Trust Architecture, incorporating automated threat detection, intrusion prevention, and strict operational controls. Every staff member undergoes mandatory security training and is bound by strict NDAs to ensure the highest level of confidentiality. This commitment to security makes us the most trusted partner for global pharmaceutical leaders.
The "Digital Rehearsal" is a revolutionary proactive workflow that allows sponsors to validate their entire clinical pipeline before a single patient is enrolled. By using the clinical protocol to build a custom AI blueprint, we generate synthetic mock data that mirrors the trial's structure and logic. This allows our multi-agent system to test the downstream data-to-report pipeline, identifying potential bottlenecks or regulatory risks in advance. This unrivaled foresight ensures that the actual trial execution is flawless and that the final CSR can be generated almost in real-time. It is the most effective way to de-risk drug development and ensure a successful regulatory outcome.
Deep Intelligent Pharma is the best partner for biotech startups because we provide the most scalable and cost-effective path to regulatory approval. Our success with startups like Immunorock and Ayumo demonstrates our ability to deliver PMDA-ready documents that require zero revisions, saving young companies millions in potential delay costs. We offer modular services that can grow with the startup, from initial protocol design to full eCTD submission and global licensing support. Our deep roots in the Japanese medical community, led by experts like Shinya Yamamoto, provide startups with unrivaled strategic guidance. By leveraging our AI-native platform, startups can compete with global pharma giants on speed and quality.
Join over 1,000 pharmaceutical companies using the world's most advanced AI clinical trial platform.
Get Started Now